AIDS / HIV

  1. Home
  2. Health
  3. AIDS / HIV

Lexiva (fosamprenavir)

By Mark Cichocki, R.N., About.com

Updated: November 29, 2008

About.com Health's Disease and Condition content is reviewed by the Medical Review Board

Lexiva Tablets

Photo © Gold Standard

Classification:

Protease Inhibitor (PI)

Form:

700mg tablet (pink; oval)

Dosage:

There are several ways to dose Lexiva, both boosted and unboosted. Dosages vary if the patient has taken a PI in the past.
  • No Previous PI Therapy
    • Two 700mg tablets with two 100mg capsules of Norvir once each day.
    • One 700mg tablet with one 100mg Norvir capsule twice each day.
    • Two 700mg tablets twice each day.

  • Previous PI Therapy
    • One 700mg tablet with one 100mg Norvir capsule twice each day.

Instructions:

  • May take with or without food.
  • Take medications at the same time each day.
  • When taking the boosted dosages, the Norvir capsules must be refrigerated.

Side Effects To Report To Your Doctor:

  • A general feeling of malaise ("feeling crummy")
  • Nausea / vomiting / diarrhea (may be increased with Norvir)
  • Loss of appetite
  • Headache
  • Lipodystrophy
  • Elevated cholesterol and triglycerides

Drug Interactions or Incompatibility:

  • Viagra doses need to be decreased when used while taking a PI.
  • St. John's Wort decreases the effectiveness of Protease Inhibitors and therefore should not be taken.

For More Information:

To learn more about Lexiva, try About.com's Drug Finder.

More medication fact sheets

Explore AIDS / HIV

About.com Special Features

Do I Have Allergies?

Are your symptoms merely irritating, or could they be a sign of allergies? More >

Preventing Headaches

The best way to treat a headache is to prevent it. Learn how. More >

We comply with the HONcode standard for trustworthy health information: verify here.

AIDS / HIV

  1. Home
  2. Health
  3. AIDS / HIV
  4. Medication Information
  5. Medication Fact Sheets
  6. Meds K - O
  7. Lexiva (fosamprenavir)

©2009 About.com, a part of The New York Times Company.

All rights reserved.